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Abstract
Immune-mediated cerebellar ataxias include gluten ataxia, paraneoplastic cerebellar degeneration, GAD
antibody associated cerebellar ataxia, and Hashimoto’s encephalopathy. Despite the identification of an
increasing number of immune-mediated cerebellar ataxias, there is no proposed standardized therapy. We
evaluated the efficacies of immunotherapies in reported cases using a common scale of daily activity. The
analysis highlighted the importance of removal of autoimmune triggering factors (e.g., gluten or cancer) and the
need for immunotherapy evaluation (e.g., corticosteroids, intravenous immunoglobulin, immunosuppressants) and
adaptation according to each subtype.
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Background
Accumulating evidence suggests that the cerebellum is
one of the main CNS targets of autoimmunity, as demon-
strated by the high prevalence of paraneoplastic cerebellar
degeneration (PCD) amongst paraneoplastic neurological
syndromes [1, 2]. Since the first description of PCD in
1919 [3], a variety of autoantibodies have been identified
associated with different neoplasms [4]. In addition to the
well-established concept of PCD, the clinical entity of
non-paraneoplastic immune-mediated cerebellar ataxias
(CAs) was established recently [5–7]. In the 1980s, some
of these cases were reported in association with autoanti-
bodies, and three clinical entities have been established
since then, based on the type of the associated antibodies
(Abs) and specific clinical features: gluten ataxia (GA),
anti-glutamic acid decarboxylase antibodies (GAD Abs)-
associated cerebellar ataxia (GAD Abs-CA), and
Hashimoto’s encephalopathy (HE). Other clinical entities
will probably emerge in the future because some autoanti-
bodies have been described recently in patients with cere-
bellar ataxia, but as only few patients have been described
in each group, further works will be necessary to confirm
autoimmune mechanisms in these patients (Table 1).
Interestingly, many of these autoantibodies recognize
cerebellar specific antigens located in Purkinje cell soma
to dendrites resulting in an immunohistochemical staining
pattern of ‘Medusa head’ and suggesting a common entity
(see Table 1) [8–10].
Prospective studies by Hadjivassiliou et al. [11] showed
a prevalence of immune-mediated CAs of 32 % among
320 patients with sporadic ataxia (GA 27 %, PCD 3 %, and
GAD Abs-CA 3 %). This suggests a higher than expected
incidence of immune-mediated CAs amongst sporadic
CAs. Thus, clinicians are currently required to establish
the diagnosis of immune-mediated CAs (IMCAs) and to
initiate immunotherapy at an early stage [1, 10].
However, there is still uncertainty regarding the type
of immunotherapy that should be used for each subtype
of immune-mediated CAs. This can be explained by the
following two reasons. Firstly, there are no large-scale
randomized studies on the optimal therapeutic strategies
in IMCAs. Due to the rarity of IMCAs, there are to date
no large-scale clinical studies in this field, though there
are few retrospective studies and case reports. This is
also confounded by the fact that in PCD, removal of the
cancer may influence the immunological process causing
the cerebellar damage. Secondly, treatment-induced im-
provement has been evaluated more or less subjectively.
Some authors used the term "improvement" loosely and
the extent of the "improvement" could not be assessed
from the provided description of the clinical course.
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Although other authors quantified the effects of treat-
ment using the International Cooperative Ataxia Rating
Scale (ICARS), small increases in the score did not ne-
cessarily correlate with improvements in daily living and
therefore could not be considered clinically significant
changes. Furthermore fluctuations in the ataxia symp-
toms and signs can be influenced by other factors such
as stress, fatigue etc. There is therefore a need to es-
timate the efficacy of immunotherapy by assessing
improvement in daily living.
The aim of this paper was to propose guidelines for man-
agement of patients with IMCAs. Specifically, (1) we col-
lected IMCAs cases described in published case reports
and retrospective studies, and (2) we assessed the efficacy
of various immunotherapies in terms of improvement of
daily activity. Our study focused on GA, PCD, and GAD
Abs-CA. First, we analyzed immunotherapies for GA and
PCD, in both of which autoimmunity is triggered by
known antigenic determinant (gluten and neoplasm,
respectively). We also analyzed immunotherapies for GAD
Abs-CA, in which there is no underlying condition that
triggers autoimmunity. The main goals were to define the
response of each subtype of IMCA to provide a rational
therapeutic strategy for each subtype that could be tested.
Gluten ataxia
What is the first line immunotherapy?
Whilst the benefits of a gluten-free diet in patients
with coeliac disease and dermatitis herpetiformis have
long been established [12], there are only a few stud-
ies on the effects of gluten-free diet on neurological
manifestations. Most are case reports primarily con-
cerning patients with established coeliac disease who
then developed clinical neurological symptoms. Such
studies described variable but overall favorable re-
sponse to gluten-free diet [12]. In their systematic
study on the effect of gluten-free diet in patients with
GA, with or without enteropathy, Hadjivassiliou et al.
Table 1 Representative autoantibodies to cerebellar antigens in immune-mediated cerebellar ataxias
Autoantibodies Conditions (When autoantibodies are associated
with neoplasms, frequency of PCD is indicated.)
Localization
Anti-Yo PCD (53 %), Breast, Uterus, Ovaries Mainly Purkinje cells and few other neurons in the molecular layer
Anti-Hu PCD (15 %), SCLC All neuronal nuclei and cytolpasm
Anti-Tr PCD (5 %), Hodgkin’s disease Purkinje cells cytoplasm and dendrites,
Anti-CV2 PCD (4 %), SCLC, thymoma Oligodendrocytes
Anti-Ri PCD (2 %), Breast All neuronal nuclei
Anti-Ma2 PCD (2 %), Testicle, Lung Nucleoli
Anti-VGCC (P/Q type) PCD (2 %), SCLC Purkinje cells, cytoplasm, dendrites and dot-staining of the molecular layer
Anti-SOX1 PCD (―), SCLC Bergman glial cell nuclei
Anti-ZIC4 PCD (―), SCLC Neuronal nuclei
PCA-2 PCD (―), SCLC Purkinje cells, cytoplasm, dendrites and dot-staining of the molecular
layer
Anti-Homer-3 a Purkinje cells, cytoplasm, dendrites and dot-staining of the molecular
layer
Anti-CARP VIII a Purkinje cells, cytoplasm, dendrites and dot-staining of the molecular
layer
Anti-PKCγ a Purkinje cells, cytoplasm, dendrites and dot-staining of the molecular
layer
Anti-Ca/ARHGAP26 a Purkinje cells, cytoplasm, dendrites and dot-staining of the molecular
layer
Anti-mGluR1 a Medusa
Anti-Sj/ITPR1 b Purkinje cells, cytoplasm, dendrites and dot-staining of the molecular layer
Anti-Nb/AP3B2 b Purkinje cells, cytoplasm, dendrites and dot-staining of the molecular
layer
Anti-GluRδ2 Para/post infectious Purkinje cells, cytoplasm, dendrites and dot-staining of the molecular layer
Anti-transglutaminase 2, 6 Gluten ataxia
Anti-GAD65 GAD Abs-CA or PCD (―) GABAergic neurons
Frequency among PCDs was evaluated based on our consensus paper [1]. PCD (―) indicates low frequency.
The localization was based on the review by Jarius and Wildemann [8].
SCLC small cell lung carcinoma, Medusa Immunohistochemistry shows ‘Medusa head’ pattern in some patients.
aAssociation of neoplasms was reported only in 1–2 patients. bConditions that trigger production of Abs are unknown.
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[12] concluded that gluten-free diet is clinically useful in
patients with GA [12]. Their study included 43 patients
with GA, and 26 who adhered to the gluten-free diet
showed serological evidence of elimination of antibodies
(treatment group, versus 14 patients of the control group
who refused the diet). In their study [12], patients of the
two groups were matched at baseline for various variables
(e.g., age, duration of CAs, severity of CAs). There were no
significant differences in baseline performance in each
ataxia test between the two groups. However, significant
improvement was observed in the performance test scores
(computerized finger-nose latency, hand or foot taping,
Peg and quantitative Romberg’s test) and in the subjective
global clinical impression scale in the treatment group
compared with the control group. The improvement was
apparent even after excluding patients with enteropathy.
The study also provided serological evidence of elimination
of anti-gliadin Abs as a confirmation of strict adherence to
the diet.
The long-term effects of strict gluten-free diet were
retrospectively examined in 371 patients with GA. Seventy
four percent of these patients had mild ataxia (patient able
to walk unaided), 16 % had moderate ataxia (patient needs
walking aid/support to walk) and 10 % had severe ataxia
(wheelchair bound). Strict gluten-free diet for one year
(with evidence of elimination of all serological tests for
gluten sensitivity) resulted in improvement of gait or
stabilization in all. Improvement was most marked in the
mild ataxia group. In the moderate and severe groups
stabilization was the norm despite MR spectroscopic evi-
dence of improvement of NAA/Cr of the vermis. There
was good correlation between the clinical severity of the
ataxia and the severity of the cerebellar atrophy. By con-
trast those patients who did not adopt a gluten free diet
continued to progress both clinically and radiologically.
Most of the patients who showed limited recovery
had radiological evidence of cerebellar atrophy. These
results suggest that strict-gluten free diet may im-
prove or stabilize GA
A small, uncontrolled study looked at the effect of intra-
venous immunoglobulins (IVIg) in the treatment of 4 pa-
tients with GA free of enteropathy [13] (Additional file 1:
Table S1). IVIg improved CAs in 3 of the 4 patients. How-
ever, these responders still showed CAs that interfered
with their daily lives. Finally, the effect of intravenous
methylprednisolone (mPSL) in GA has not been reported
so far.
Prognostic factors
Despite adherence to gluten-free diet, few patients show
gradual progression of CAs [14]. In general, such pa-
tients have cerebellar atrophy before diagnosis and
started on the diet long after the onset of CAs. However,
such cases are rare and by far the commonest cause of
lack of response correlates with poor adherence to
gluten-free diet [15, 16]. Other reasons include the pres-
ence of small amounts of gluten in most gluten-free
products. In patients with high sensitivity to gluten, a
minute amount of gluten is enough to cause cerebellar
damage [15, 16]. In those patients who continue to be
positive for anti-gliadin Ab despite strict adherence,
wheat-free diet should be considered first before
embarking on immunosuppressive therapy [16].
Immunotherapy for gluten-free resistant patients
Trials were reported for patients who failed to respond to
gluten-free diet (though hypersensitivity to a small amount
of gluten in gluten-free products could not be ruled out)
[14, 17] (Additional file 1: Table S1). The MRI of these
studied patients showed evident atrophy of the cerebellar
vermis. Souayah et al. [14] reported three patients who
were treated with IVIg whose CAs and neuropathic pain
(small fiber neuropathy syndrome) were resistant to strict
gluten-free diet. All three patients responded to the IVIg
induction therapy. The effectiveness of such therapy was
confirmed by worsening of CAs upon discontinuation of
IVIg in two patients. Accordingly, these patients were
treated with a maintenance dose of IVIg, which produced
stabilization of clinical symptoms. Consistent with these re-
sults, Nanri et al. [17] reported a transient response to IVIg
in two patients with GA. These results suggest that con-
tinuous immunosuppression is necessary in such patients.
Thus, maintenance therapy with IVIg or immunosuppres-
sants (mycophenolate, cyclosporin, cyclophosphamide, and
mycophenolate mofetil) should be considered for long-
term follow-up of patients who fail to respond to gluten-
free diet provided that the patient is negative for all sero-
logical gluten-related antibodies [16].
Immunotherapies for GA subtypes
Some patients with gluten-related disorders present with
myoclonus ataxia and refractory coeliac disease [18].
The myoclonus is cortical in origin and sometimes wide-
spread. This entity is rare and 9 patients were reported
among more than 600 patients with neurological mani-
festations of gluten-related disorders [18]. In spite of
strict gluten-free diet, five of these 9 patients presented
with persistent symptoms of malabsorption and evidence
of on-going enteropathy on biopsies, and two patients
developed enteropathy-associated lymphoma. Unlike
CAs in GA, both the myoclonus and CAs respond
poorly to gluten-free diet. Nevertheless, immunosup-
pression with mycophenolate mofetil improved to some
extent both CAs and duodenal histopathological abnor-
malities [18]. The most disabling symptom remained
the myoclonus. Anticonvulsants prevented secondary
generalized seizures in all patients who had experienced
seizures [18].
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In conclusion, there is no convincing evidence that ei-
ther mPSL or IVIg therapy is superior to gluten-free diet
in GA. Based on the pathomechanism of gluten sensitivity,
gluten-free diet, which can help eliminate triggering anti-
gens, should be tried first. Strict gluten-free diet resulted
in improvement or limited improvement of CAs in most
cases. IVIg or immunosuppressants should be considered
only if strict adherence to gluten-free diet (monitored by 6
monthly serological testing of anti-gliadin antibodies) for
at least one year fails to result in any improvement in CAs
or if CAs deteriorate rapidly [12].
Paraneoplastic cerebellar degeneration
What is the first line of immunotherapy?
The clinical outcome of patients with PCD is usually
poor, but vary according the associated autoantibody
[19]. Tumor excision and physiotherapy are currently
the cornerstone of the treatment. The survival time of
patients who receive antitumor therapy is significantly
longer than those who do not [20, 21]. Depending on
the cancer type, surgery, radiotherapy or chemotherapies
should be first considered in order to prevent metastasis
and remove antigens that trigger immune-mediated
processes [22].
The response to immunotherapy is often disappointing.
Previous studies indicated that immunotherapies did not
substantially improve CAs in patients with successfully
treated malignancies [1, 20–23]. Furthermore, fewer than
10 % of patients with PCD respond to various immuno-
therapies [24]. Two long-term follow-up studies deserve
discussion [22, 23]. Candler et al. [23] examined the out-
come of long-term follow-up of 63 patients with paraneo-
plastic neurological disease, including 13 patients with
PCD. These patients received various combinations of
anti-cancer therapies, with or without immunotherapies
(e.g., corticosteroids, intravenous immunoglobulins (IVIg),
and/or plasma exchange). The median survival time of pa-
tients with PCD was 42 months (95 % CI 32–52). Three
PCD patients (23.1 %) had died by last follow-up. Among
the total number of patients with paraneoplastic neuro-
logical syndrome, 17 (26.9 %) died with a median survival
time from onset of neurological symptoms of 43 months.
Unfortunately, the cause of death (oncological or neuro-
logical) was not determined for individual cases. Neuro-
logical outcome was associated only with treatment of the
tumor. In another study, Keime-Guibert et al. [22]
examined the effects of immunotherapy in 16 PCD
patients associated with anti-Hu (n = 10) and anti-Yo
(n = 6) Abs. These patients received one to nine cycles of
the combination of IVIg, intravenous methylprednisolone
(mPSL), and cyclophosphamide. In their study, clinical
improvement represented a change in Rankin score of
at least 1 point, while stabilization represented lack of
change in the same score after three courses of the
combination therapy. Based on these criteria, none of
the 16 patients showed improvement, while 3 of 9 pa-
tients with Rankin scale of ≤3 showed stabilization of
CAs for 4, 16 and 35 months, respectively. The me-
dian survival time from beginning of immunotherapy
was 10.2 months (range, 2–38) and 14 patients died
during follow-up (88 %). Of these, death was cancer-
related in 9 patients, neurological disease-related in 3, and
unknown reason in 2 patients (suicide? or unknown).
Thus, at the end of follow-up, only 2 patients were alive.
Taken together, these long-term follow-up studies suggest
that PCD with Hu or Yo-Abs are associated with severe
CAs resistant to immunotherapy (including combination
therapies).
Apart from the above long-term follow-up studies,
several other retrospective studies and case reports have
suggested the beneficial effects of corticosteroids and
IVIg in patients with anti-Hu or anti-Yo antibodies
(Additional file 2: Table S2) [25–31]. Among 9 re-
sponders, 1 patient received mPSL + cyclophosphamide,
2 patients IVIg, 1 patient IVIg + plasma exchange, 3 pa-
tients cyclophosphamide, 1 patient IVIg + oral prednisol-
one (PSL) + cyclophosphamide, and 1 patient IVIg + oral
PSL + rituximab. The mean follow-up period ranged
from 4 months to 10 years (median 33.9 months). Of
these studies, Voltz [20] proposed a trial of immunother-
apies after cancer treatment in patients with PCD. Specif-
ically, the treatment regimen comprises one course of
mPSL, followed 1 or 2 weeks later in case of lack of re-
sponse by administration of IVIg. Lack of response to IVIg
should be followed 1 or 2 weeks later by plasma exchange
or cyclophosphamide.
Prognostic factors
There are no specific studies on the prognosis of PCD
according to associated autoantibodies. However, prog-
nosis seems to vary depending on the nature of the asso-
ciated ONA. In some cases, such as PCD with Yo-Abs,
cerebellar ataxia is clearly due to Purkinje cell death and
neurological improvement is unlikely. The objective of
treatment will be to stop the immune process resulting
in neuronal death. In other cases, a neuronal blockage
can be suspected before secondary neuronal death oc-
curs and in these cases, immunomodulator treatment
and tumor removal become an emergency. For example,
anti-Tr/DNER-associated PCD is particularly remarkable
for the improvement observed after efficient treatment
of the associated lymphoma, irrespective of additional
immunotherapy [32]. Furthermore, some patients with
anti-Ri Ab also seem to respond well to immunotherapy
[33]. This is by contrast to the poor prognosis of PCD
with Yo, Hu or CV2/CRMP5-Abs suggesting different
pathological mechanisms for each subtypes of paraneo-
plastic antibodies [34]. Finally some authors suggested
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that early introduction of immunotherapy could be asso-
ciated with better outcome [20]. The data demonstrate
the need for future prospective studies comparing
patient outcomes and immunomodulator treatment
responses based on associated autoantibodies [35].
Anti-GAD Abs associated cerebellar ataxia
What is the first line immunotherapy?
Although various types of immunotherapies have been
used in patients with GAD Abs-CA, most patients de-
velop significant disability with poor prognosis [1, 7].
Short-term follow-up
Table 2 summarizes the effects of induction therapies in
20 patients with short-term follow-up [36–50] (see also
Additional file 3: Table S3). Classification of patients into
two types (subacute and chronic types) demonstrated
good response to immunotherapy in patients with sub-
acute type. The onset of CAs was defined as subacute
when CAs reached their NADIR or required neuro-
logical assessment within the first 3 months of symptom
presentation [51]. In subacute types, 4 (67 %) of the 6
tested patients showed excellent response to immuno-
therapy. The induction therapy included intravenous
methylprednisolone (mPSL) (n = 2), combination of
intravenous immunoglobulins (IVIg) and plasma exchange
(n = 1), combination of IVIg and rituximab (n = 1), and
plasma exchange followed by rituximab (n = 2). In contrast,
in patients with the chronic type, only 9 of the tested 19
cases (42 %) showed high response to immunotherapy.
The induction therapies used in these patients were mPSL
(n = 5), combination of mPSL and IVIg (n = 1), combin-
ation of mPSL and plasma exchange (n = 2), oral prednisol-
one (PSL) (n = 1), IVIg (n = 6), combination of IVIg and
rituximab (n = 2), and plasma exchange (n = 2). While vari-
ous types of immunotherapies were used in combination
to reduce the severity of CAs, this approach suggests
difficulties of remission in the chronic type. Further-
more, during induction therapy, relapses occurred
more frequently in the chronic type than in the sub-
acute type. Amelioration of CAs following immuno-
therapy in patients with subacute and chronic types
was associated with simultaneous decrease in GAD-
Abs titers in most cases.
Long-term follow-up
Recently, Arińo et al. [51] reported a retrospective study
on the long-term effect of immunotherapy in patients
with GAD Abs-CA [51]. In their study, 20 patients re-
ceived immunotherapies (IVIg in 10, mPSL in 9, includ-
ing mPSL alone in 4, mPSL + IVIg in 4, and mPSL +
rituximab in 1, and oral PSL in 1), while 5 patients were
not treated. Seventeen of the 20 treated patients received
maintenance therapy, including 6 patients who received
repeated IVIg during a median period of 56.2 months
(24.4–121.5 months), and 11 who received one or com-
bination of oral PSL, azathioprine, or mycophenolate
mofetil. The median follow-up period was 5.4 years
(3.1–10.3 years). The results can be summarized as
follows. First, patients who received no immunother-
apy showed progression of CAs. 2 of 5 patients
showed moderately severe disabilities; they could not
attend to own bodily needs without assistance, and
could not walk unaided. One patient was bedridden.
Second, immunotherapy improved CAs in 5 of 7 patients
(71 %) patients with subacute type, similar to the results
of short-term follow-up (prevalence of high response:
67 %). Three of these five patients showed no significant
disability, and were able to carry out all usual activities
despite some CAs. In contrast, the efficacy of immuno-
therapy was limited in patients with chronic type (2 of 13
patients, 15 %), which is in contrast to the literature
surveys of short-term follow-up in 20 patients (pro-
portion of patients who showed high response: 42 %).
Even after immunotherapy, 3 patients still required
help in daily living activities, although they were able
to walk unaided, and 4 patients were unable to attend
to own bodily needs without assistance, and unable to
walk unaided.
Arińo et al. [51] assessed the long-term outcome of
immunotherapy using modified Rankin Scale. In that
study, immunotherapy was considered effective when
Table 2 Efficacies of induction therapy in 20 previously
reported patients with anti-GAD antibodies associated cerebellar
ataxia. Data based on short-term follow-up
High responders Low responders No change Sum
Subacute type
mPSL 2 0 0 2
IVIg + PE 0 0 1 1
IVIg + R 1 0 0 1
PE + R 1 0 1 2
Sum 4 0 2 6
Chronic type
mPSL 2 1 2 5
mPSL + IVIg 0 1 0 1
mPSL + PE 1 1 0 2
oral PSL 0 1 0 1
IVIg 3 1 2 6
IVIg + R 0 1 1 2
PE 2 0 0 2
Sum 8 6 5 19a
aSince two of 14 patients were repeatedly treated due to relapse, the number
of therapies was 19.
mPSL intravenous methylprednisolone, oral PSL oral prednisolone, IVIg
intravenous immunoglobulins, PE plasma exchange, R rituximab
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the score improved by more than 1 point. Thus, the re-
sponse to immunotherapy documented in short-term
follow-up would be too small and insufficient for im-
provement in daily lives. Another reason for the poor re-
sponse in the chronic type is the progressive nature of
the chronic type. CA was progressive in 5 of the 12 pa-
tients with chronic type, suggesting that efficacies in the
chronic type do not persist in the long-term. These in-
herent properties are different from the subacute type.
In patients with subacute type, most of whom received
maintenance therapies, the remaining CA was stable
(4 of 6 patients), and progression was observed only in 1
of 6 patients. The third finding obtained from long-term
studies is the factor responsible for the good response; pa-
tients with good outcome had a better modified Rankin
Scale score at diagnosis than patients with bad outcome.
Finally, Arińo et al. [51] did not recommend any particular
type of immunotherapy.
In conclusion, there is no standardized immunother-
apy for patients with subacute GAD Abs-CA. Induction
therapies should include the combination of mPSL, IVIg,
plasma exchange and rituximab to reduce CAs as much
as possible, followed by maintenance therapies, such as
oral PSL, azathioprine, mycophenolate mofetil, or re-
peated IVIg. Immunotherapy can result in long-term im-
provement of CAs in most patients. On the other hand,
immunotherapy of patients with chronic type of GAD
Abs-CA is often ineffective; it induces limited improve-
ment in most patients, who sometimes show progression
during long-term follow-up.
Immunotherapies for subtypes of GAD Abs-CA
Previous studies reported a group of CA patients associ-
ated with low-titers of GAD Abs (<100 U/ml) [52]. The
high- and low-titer GAD Abs-CAs could be due to differ-
ent pathomechanisms. In the low-titer type, 1) GAD Abs
index is not necessarily beyond >1.0 (i.e., GAD Abs are not
necessarily produced intrathecally), and 2) GAD-Abs titer
does not necessarily decrease with improvement in CAs
(i.e., changes in GAD-Abs do not correlate with improve-
ments in CAs), which is in contrast to the high-titer type.
Previous reports showed good response to immuno-
therapies [52–55]. Five of the 6 reported patients so far
showed response to immunotherapies (Additional file 4:
Table S4). The immunotherapies used included IVIg
(n = 2), mPSL (n = 1), oral PSL (n = 2), and combination of
mPSL and oral PSL (n = 1). However, long-term prognosis
remains uncertain. Further accumulation of patients with
low-titer GAD Abs-CA is necessary for full assessment of
effects of immunotherapy and the possible association with
other associated autoantibodies must be carefully studied.
Finally there is some evidence of overlap between
some anti-GAD associated ataxias and gluten ataxia
[56]. It is therefore important to look for serological
evidence of gluten sensitivity in patients with anti-GAD
antibodies as gluten free diet in such cases may be a use-
ful therapeutic intervention.
Hashimoto’s encephalopathy
Cerebellar type of Hashimoto’s encephalopathy (HE) has
been diagnosed based on the following criteria, (1) ele-
vated anti-thyroid antibodies and (2) responsiveness to
corticosteroids [1, 6, 57–62]. A series of reports have
shown underlying immune-mediated mechanisms. How-
ever, its clinical entity is still controversial because of no
evidence establishing a direct correlation between anti-
thyroid antibodies (Abs) and ataxia given the high preva-
lence of anti-thyroid Abs in the normal population [1].
Consequently, there is overlapping between HE, diag-
nosed based on the above criteria, and other subtypes of
IMCAs. Indeed, patients with GA or GAD Abs-CA often
have anti-thyroid Abs [17, 52]. Pathophysiological fea-
tures of patient’s CSF are also heterogeneous [63]. Taken
together, further long-term systematic studies are needed
to examine how steroid-responsive IMCA associated
with anti-thyroid Abs (in the absence of anti-GAD and
gluten antibodies) is clinically categorized.
On the other hand, there is a group of patients with
anti-thyroid Abs who showed characteristically good re-
sponse to immunotherapies when compared with other
subtypes of IMCAs [61]. Interestingly, some patients
showed full recovery. Table 3 summarizes the effects of
immunotherapies (corticosteroids and intravenous immu-
noglobulins (IVIg)) in 13 patients reported by Matsunaga
et al. [61]. Corticosteroids were administrated in 12 of
these patients. Before the therapy, their CAs severely
affected their daily lives. 11 patients were not able to walk
unaided, though one patient walked without support but
with considerable staggering, difficulties in half turn.
Treatment with corticosteroids resulted in full recovery in
Table 3 Efficacies of immunotherapies in patients with
Hashimoto’s encephalopathy
Full recovery Improvement Limited
improvement
Sum
oral PSL 1 1 0 2
mPSL 1 0 2 3
mPSL + oral PSL 2 2 1 5
mPSL + oral PSL + IS 0 0 1 1
mPSL + IVIg 0 1 0 1
IVIg + IS 0 0 1 1
Sum 4 4 5 13
Improvement: patients started to walk without support and looked after their
own affairs without help. Limited recovery: Unaided walking was
still impossible.
These data were based on published studies by Matsunaga et al. [58] and
personal communication with the authors.
mPSL intravenous methylprednisolone, oral PSL oral prednisolone, IVIg
intravenous immunoglobulins, IS immunosuppressants
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4 patients ("Full recovery" in Table 3), and 4 patients
started to walk without support (although with irregular
stepping and instability) and to look after their own affairs
without help ("Improvement" in Table 3). Another four
patients showed improvement of limb ataxia, though un-
aided walking was still difficult ("Limited improvement" in
Table 3). Oral prednisolone (PSL) was used in 2 of the 12
patients while the other 10 received methylprednisolone
(mPSL) intravenously first followed in 7 patients by either
oral PSL, IVIg or azathioprine. There were no significant
differences between oral PSL and mPSL, or between
mPSL + posttherapy (PSL, IVIg or azathioprine) and
mPSL alone. On the other hand, IVIg was administrated
in one of the 13 patients due to diabetes mellitus though
it was later switched to cyclophosphamide. This patient
could not walk unaided before treatment but limb ataxia
improved slightly after IVIg, though unaided walking was
still impossible. The above data do not favor IVIg relative
to corticosteroids but rather suggest that corticosteroids
should be considered first in the treatment.
Excellent response to immunotherapy in HE correlated
significantly with positivity for anti-NH2-terminal of α-
enolase (NAE) Abs [61]. NAE-Abs titer decreased after
the successful steroid therapy in some patients [62]. Im-
portantly, Matsunaga et al. [61] also concluded that the re-
sponse to immunotherapy in HE did not correlate with
the latency between CAs onset and initiation of such ther-
apy. Two patients with latency to treatment of 10 years
responded well to corticosteroids (Patients # 2 and 9
showed full and good recovery, respectively) and both had
no cerebellar atrophy on MRI. These results suggest that
immune-mediated cell loss would be slow characteristic-
ally in some patients with steroid-response IMCA associ-
ated with anti-thyroid Abs, resulting in a chance of
satisfactory improvement using immunomodulators.
Conclusion
In this review, we evaluated the efficacy of each im-
munotherapy based on case reports and retrospective
studies. When CAs are triggered by certain known anti-
genic stimulants, priority should be directed towards
treatment of the underlying conditions. For example,
gluten-free diet in GA and removal of neoplasms in
PCD. In cases where CAs progress after treatment of the
underlying condition, immunotherapy should follow.
On the other hand, when CAs are not triggered by any
other condition (e.g., in GAD Abs-CA and steroid-re-
sponse IMCA associated with anti-thyroid antibodies), in-
duction immunotherapies is provided first to minimize
CAs, followed by maintenance immunotherapy to pre-
vent relapse. Various combinations of immunotherapies
Table 4 Reported first line immunotherapy for each subtype of
immune-mediated cerebellar ataxias
Gluten ataxia
Induction and maintenance therapies: strict gluten-free diet
(In case of no improvement and negative gluten related antibodies,
immunosuppressants or IVIg )
Paraneoplastic cerebellar degeneration
Quick removal of neoplasm must be the first objective of treatment
Induction therapy as soon as possible: mPSL, IVIg,
immunosuppressants, or/and plasma exchange
Discussion according associated Abs
Maintenance therapy: continuous oral PSL, IVIg, immunosuppressants
Anti-GAD Abs associated cerebellar ataxia
Induction therapy: mPSL, IVIg, immunosuppressants, plasma exchange,
or/and rituximab
Maintenance therapy: continuous oral PSL, IVIg, immunosuppressants,
or/and rituximab
Abs antibodies, mPSL intravenous methylprednisolone, oral PSL oral
prednisolone, IVIg intravenous immunoglobulins
a b c d e f
Fig. 1 The clinical time-course could be classified into 6 patterns; a full recovery type, b partial recovery type, c stabilization type, d fluctuated
type, e gradually progressive type, and f rapidly progressive type. Triangle indicates the time of immunotherapy. Possible clinical courses for each
subtype are schematically indicated below. Black indicates ‘common course’, gray ‘occasional course’, and light gray ‘rare course’. GA gluten ataxia,
PCD paraneoplastic cerebellar degeneration, GAD anti-GAD Antibodies associated cerebellar ataxia. HE Hashimoto’s encephalopathy, The clinical
entity of HE is still controversial. Thus, we show the time-course of steroid-response IMCA associated with anti-thyroid Abs.
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have been used, ranging from IVIg, corticosteroids,
immunosuppressants, plasmapheresis, and rituximab,
depending on the subtype of IMCAs (Table 4).
Previous studies suggested the presence of two distinct
groups with IMCAs, the good response group, which in-
cludes GA and steroid-response IMCA associated with
anti-thyroid antibodies, and poor response group, which
includes GAD Abs-CA and PCD. Furthermore, the clin-
ical time-course can be classified into 6 patterns; (a) full
recovery type, (b) partial recovery type, (c) stabilization
type, (d) fluctuating type, (e) gradually progressive type,
and (f) rapidly progressive type (Fig. 1). These clinical
courses are possibly determined by mainly two factors, re-
sponsiveness to immunotherapies and severity of cerebellar
atrophy. Progression can be halted when the immune-
mediated mechanisms are controlled by immunotherapy.
When neural damage caused by the immune processes can
be prevented by immunotherapy, the extent of cerebellar
cell loss determines the recovery course, full recovery, par-
tial recovery, or stabilization. Most patients with GA and
steroid-response IMCA associated with anti-thyroid anti-
bodies exhibit such clinical courses. In contrast, when the
immune mechanism underlying CAs is resistant to
immunotherapy, the clinical course would be either of
fluctuated type, gradually progressive type, or progressive
type. Most of patients with GAD Abs-CA and PCD show
these types.
Suspicion of IMCA is the first step towards early diagno-
sis. There is no clear cut clinical characteristics that enable
the diagnosis of IMCAs. On imaging, vermian involvement
seems more prevalent in IMCAs by comparison to degen-
erative (MSA-C) and genetic ataxias. Rapidity of progres-
sion is a characteristic feature of PCD. In clinical practice
patients presenting with ataxia without a family history
should be investigated for all possible causes. IMCAs-
related antibodies should be examined [1]. Even in the ab-
sence of such antibodies immune mediated ataxia may still
be a possibility. The term primary autoimmune cerebellar
ataxia (PACA) has been proposed to describe such entity
[11]. It is likely that PACA would be equally responsive to
immunomodulation. IMCAs should be diagnosed early if
possible. We reported previously the preservation of cere-
bellar function after treatment at an early stage, prior to
the development of cerebellar atrophy [1]. The develop-
ment of effective therapeutic approaches then becomes es-
sential in the treatment of IMCAs.
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